Replies to post #224786 on Anavex Life Sciences Corp (AVXL)

[rayovacAAA]

NO ENROLLMENT UPDATE FOR THE US RETT PLACEBO CONTROLLED TRIAL CURRENTLY STILL LABELED AS RECRUITING WAS PROVIDED IN THE PR THIS MORNING.


Https://clinicaltrials.gov/ct2/show/NCT03758924?term=Anavex&draw=2&rank=

Recruitment Status: Recruiting

https://www.anavex.com/anavex-life-sciences-announces-preliminary-clinical-efficacy-data-of-its-u-s-phase-2-clinical-trial-of-anavex2-73-in-patients-with-rett-syndrome/

Preliminary Clinical Data is derived from the ANAVEX®2-73-RS-001 study on the first 6-patient cohort ranging in age from 18 to 36 years, who completed the pharmacokinetic (PK) part of the study and who received a low dose of approx. 5 mg daily oral liquid dose of ANAVEX®2-73 (blarcamesine) for 7 weeks. Patients are continuing participation in the ANAVEX®2-73-RS-001 open label extension study.

[SquealingSquid]

Alzheimer’s and PDD has both extension info and % of patients enrolled, Rett Syndrome has only extension info, I’m wondering why they are not sharing the percentage of patients enrolled